Moreover, the use of a corticotropin-releasing hormone receptor 1 (CRHR1) antagonist has been shown to reduce oxidative stress by inhibiting the Keap1-Nrf2-p62 pathway, thereby alleviating depression-like behaviors in PSD by reducing abnormal p62 accumulation (32). Here, CRHR1 is linked to depressive symptom measurement.